JointHealth
français
 
JointHealth™ express   May 20, 2021

Let BC PharmaCare hear "Your Voice" on upadacitinib (Rinvoq™) for the treatment of psoriatic arthritis in adults

Upadacitinib (Rinvoq™) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about upadacitinib for the treatment of psoriatic arthritis in adults.
You can give input if you are a B.C. resident and have psoriatic arthritis, a caregiver to someone with psoriatic arthritis, or if your group represents people who live with psoriatic arthritis.

If you would like our help in providing your input, you can email your comments to feedback@jointhealth.org or call us at 604-974-1366. Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Monday, June 14 so that we may submit the questionnaire in time for the deadline.

The submission deadline is midnight on June 16, 2021. Patients and caregivers may give their input directly through the links below.

Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
  • To view the information sheet for upadacitinib for the treatment of psoriatic arthritis in adults: click here
  • To complete the Questionnaire as a patient, caregiver, or patient group representative: click here